Detail Information of Post-Translational Modifications

General Information of Drug Transporter (DT)
DT ID	DTD0277 Transporter Info
Gene Name	SLC30A9
Transporter Name	Zinc transporter 9
Gene ID	10463
UniProt ID	Q6PML9

Post-Translational Modification of This DT
Overview ofSLC30A9 Modification Sites with Functional and Structural Information
Sequence	M L P G L A A A A A H R C S W S S L C R L R L R C R A A A C N P S D R Q E W Q N L V T F G S F S N M V P C S H P Y I G T L S Q V K L Y S T N V Q K E G Q G S Q T L R V E K V P S F E T A E G I G T E L K A P L K Q E P L Q V R V K A V L K K R E Y G S K Y T Q N N F I T G V R A I N E F C L K S S D L E Q L R K I R R R S P H E D T E S F T V Y L R S D V E A K S L E V W G S P E A L A R E K K L R K E A E I E Y R E R L F R N Q K I L R E Y R D F L G N T K P R S R T A S V F F K G P G K V V M V A I C I N G L N C F F K F L A W I Y T G S A S M F S E A I H S L S D T C N Q G L L A L G I S K S V Q T P D P S H P Y G F S N M R Y I S S L I S G V G I F M M G A G L S W Y H G V M G L L H P Q P I E S L L W A Y C I L A G S L V S E G A T L L V A V N E L R R N A R A K G M S F Y K Y V M E S R D P S T N V I L L E D T A A V L G V I I A A T C M G L T S I T G N P L Y D S L G S L G V G T L L G M V S A F L I Y T N T E A L L G R S I Q P E Q V Q R L T E L L E N D P S V R A I H D V K A T D L G L G K V R F K A E V D F D G R V V T R S Y L E K Q D F D Q M L Q E I Q E V K T P E E L E T F M L K H G E N I I D T L G A E V D R L E K E L K K R N P E V R H V D L E I L
PTM type	X-Malonylation X-Oxidation X-Phosphorylation X-Ubiquitination X: Amino Acid

Malonylation
Lysine	3 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon1	Have the potential to influence SLC30A9			[1]
Role of PTM	Potential impacts
Modified Residue	Lysine	Modified Location	374
Experimental Method	Co-Immunoprecipitation
Detailed Description	Malonylation at SLC30A9 Lysine 374 has the potential to affect its expression or activity.
PTM Phenomenon2	Have the potential to influence SLC30A9			[1]
Role of PTM	Potential impacts
Modified Residue	Lysine	Modified Location	479
Experimental Method	Co-Immunoprecipitation
Detailed Description	Malonylation at SLC30A9 Lysine 479 has the potential to affect its expression or activity.
PTM Phenomenon3	Have the potential to influence SLC30A9			[1]
Role of PTM	Potential impacts
Modified Residue	Lysine	Modified Location	487
Experimental Method	Co-Immunoprecipitation
Detailed Description	Malonylation at SLC30A9 Lysine 487 has the potential to affect its expression or activity.
Oxidation
Cystine	1 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon1	Have the potential to influence SLC30A9			[2]
Role of PTM	Potential impacts
Modified Residue	Cystine	Modified Location	141
Experimental Method	Co-Immunoprecipitation
Detailed Description	Oxidation at SLC30A9 Cystine 141 has the potential to affect its expression or activity.
Phosphorylation
Serine	4 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon1	Have the potential to influence SLC30A9			[3]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	88
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC30A9 Serine 88 has the potential to affect its expression or activity.
PTM Phenomenon2	Have the potential to influence SLC30A9			[3]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	183
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC30A9 Serine 183 has the potential to affect its expression or activity.
PTM Phenomenon3	Have the potential to influence SLC30A9			[4]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	303
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC30A9 Serine 303 has the potential to affect its expression or activity.
PTM Phenomenon4	Have the potential to influence SLC30A9			[5]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	471
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC30A9 Serine 471 has the potential to affect its expression or activity.
Ubiquitination
Lysine	4 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon1	.			[6]
Role of PTM	Potential impacts
Modified Residue	Lysine	Modified Location	73
Experimental Method	Co-Immunoprecipitation
Detailed Description	Ubiquitination at SLC30A9 Lysine 73 has the potential to affect its expression or activity.
PTM Phenomenon2	.			[6]
Role of PTM	Potential impacts
Modified Residue	Lysine	Modified Location	223
Experimental Method	Co-Immunoprecipitation
Detailed Description	Ubiquitination at SLC30A9 Lysine 223 has the potential to affect its expression or activity.
PTM Phenomenon3	.			[6]
Role of PTM	Potential impacts
Modified Residue	Lysine	Modified Location	223
Experimental Method	Co-Immunoprecipitation
Detailed Description	Ubiquitination at SLC30A9 Lysine 223 has the potential to affect its expression or activity.
PTM Phenomenon4	.			[6]
Role of PTM	Potential impacts
Modified Residue	Lysine	Modified Location	223
Experimental Method	Co-Immunoprecipitation
Detailed Description	Ubiquitination at SLC30A9 Lysine 223 has the potential to affect its expression or activity.

References
1	Proteomic and Biochemical Studies of Lysine Malonylation Suggest Its Malonic Aciduria-associated Regulatory Role in Mitochondrial Function and Fatty Acid Oxidation. Mol Cell Proteomics. 2015 Nov;14(11):3056-71.
2	A Quantitative Tissue-Specific Landscape of Protein Redox Regulation during Aging. Cell. 2020 Mar 5;180(5):968-983.e24.
3	Phosphoproteomic screening identifies Rab GTPases as novel downstream targets of PINK1. EMBO J. 2015 Nov 12;34(22):2840-61.
4	Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics. 2014 Jul;13(7):1690-704.
5	Defeating Major Contaminants in Fe3+- Immobilized Metal Ion Affinity Chromatography (IMAC) Phosphopeptide Enrichment. Mol Cell Proteomics. 2018 May;17(5):1028-1034.
6	ActiveDriverDB: human disease mutations and genome variation in post-translational modification sites of proteins. Nucleic Acids Res. 2018;46(D1):D901-D910.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.

Detail Information of Post-Translational Modifications

Visitor Map

Correspondence